Physicochemical properties of drugs and membrane permeability

South African Journal of Science

Volumn 98, Issue 7-8, 2002, Pages 385-391

  Malan, S F ^a   Chetty, D J ^a   Du Plessis, J ^a  

^a NORTH WEST UNIVERSITY   (South Africa)

Author keywords

[No Author keywords available]

Indexed keywords

MEMBRANE TECHNOLOGY; PHARMACEUTICAL INDUSTRY; PHYSICOCHEMICAL PROPERTY;

EID: 0036629696     PISSN: 00382353     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (78)

1. Chetty D.J., Chen L.H., Lin S.S. and Chien Y.W. (1998). Evaluation of physicochemical and solvatochromic descriptors in quantitative structure-buccal permeability relationships. AAPS PharmSci. 1(1), S93.
2. Abraham M.H., Chada H.S. and Mitchell R.C. (1995). The factors that influence skin penetration of solutes. J. Pharm. Pharmacol. 47, 8-16.
3. Diez-Sales O., Watkinson A.C., Herraez-Domininguez M., Javaloyes C. and Hadgraft J. (1996). A mechanistic investigation of the in vitro human skin permeation enhancing effect of Azone® Int. J. Pharm. 129, 33-40.
4. De Vries H.E., Kuiper J., De Boer A.G., Van Berkel T.J.C. and Breimer D.D. (1997). The blood-brain barrier in neuroinflammatory diseases. Pharmacol. Rev. 49(2), 143-156.
5. Ehrlich P. (1885). Das Sauerstoffbeduerfnis des Organismus: Eine Farbenanalytiche Studie, vol. 8, p. 167. Hirschwald, Berlin.
6. Reese T.S. and Karnovsky M.J. (1967). Fine structural localisation of a blood-brain barrier to exogenous peroxidase. J. Cell. Biol. 34(1), 207-217.
7. Burton P.S., Conradi R.A., Ho N.F.H., Hilgers A.R. and Borchardt R.T. (1996). How structural features influence the biomembrane permeability of peptides. J. Pharm. Sci. 85(12), 1336-1340.
8. Reichel A. and Begley D.J. (1998). Potential of immobilised artificial membranes for predicting drug penetration across the blood-brain barrier. Pharm. Res. 15(8), 1270-1274.
9. Goldstein G.W. and Betz A.L. (1986). The blood-brain barrier. Sci. Am. 255, 74-83.
10. Greig N.H. (1987). Optimising drug delivery to brain tumors. Cancer Treat. Rev. 14(1), 1-28.
11. Jangiro D., Leaman S.M. and Stannes K.A. (1999). Dynamic in vitro modelling of the blood-brain barrier: A novel tool for studies of drug delivery to the brain. Pharm. Sci. Technol. Today 2(1), 7-12.
12. Schinkel A.H. (1999). P-glycoprotein, a gatekeeper in the blood-brain barrier. Adv. Drug Deliv. Rev. 36, 179-194.
13. Terasaki T. and Tsuji A. (1994). Drug delivery to the brain utilising blood-brain barrier transport systems. J. Control. Rel. 29, 163-169.
14. Gaillard P.J. and De Boer A.G. (2000). Relationship between permeability status of the blood-brain barrier and in vitro permeability coefficient of the drug. Eur. J. Pharm. Sci. 12, 95-102.
15. Bates L.P. (1984). The blood-brain barrier and central nervous system drug penetration. Pharm. J. 232, 265-268.
16. Chien Y.W. (1992). Novel Drug Delivery Systems, 2nd Edn. Marcel Dekker, New York.
17. Nair M. and Chien Y.W. (1993). Buccal delivery of progestational steroids. Part 1. Characterization of barrier properties and effect of penetrant hydrophilicity. Int. J. Pharm. 89, 41-49.
18. Guy R.H. and Hadgraft J. (1989). Selection of drug candidates for transdermal drug delivery. In Transdermal Drug Delivery. Developmental Issues and Research Initiatives, eds J. Hadgraft and R.H. Guy, pp. 59-81. Marcel Dekker, New York.
19. Guy R.H. (1996). Current status and future prospects of transdermal drug delivery. Pharm. Res. 14, 1765-1769.
20. Levin V.A. (1980). Relationship of octanol/water partition coefficient and molecular weight to rat brain capillary permeability. J. Med. Chem. 23(6), 682-684.
21. Sawada G.A., Barsuhn C.L., Lutzke B.S., Houghton M.E., Padbury G.E., Ho N.F.H. and Raub T.J. (1999). Increased lipophilicity and subsequent cell partitioning decrease passive transcellular diffusion of novel, highly lipophilic antioxidants. J. Pharmacol. Exp. Ther. 288(3), 1317-1326.
22. Van Bree J.B.M.M., De Boer A.G., Danhof M., Ginsel L.A. and Breimer D.D. (1988). Characterisation of an in vitro blood-brain barrier: Effects of molecular size and lipophilicity on cerebrovascular endothelial transport rates of drugs. J. Pharmacol. Exp. Ther. 247(3), 1233-1239.
23. Fenart L., Casanova A., Dehouck B., Duhem C., Slupek S., Cecchelli R. and Betbeder D. (1999). Evaluation of the effect of charge and lipid coating on ability of 60 nm nanoparticles to cross an in vitro model of the blood-brain barrier. J. Pharmacol Exp. Ther. 291(3), 1017-1022.
24. Hanch C., Steward A.R., Anderson S.M. and Bentley D. (1967). The parabolic dependence of drug action upon lipophilic character as revealed by a study of hypnotics. J. Med. Chem. 11(1), 1-11.
25. 2 receptor histamine antagonists. J. Med. Chem. 31, 656-671.
26. Leo A., Hansch C. and Elkins D. (1971). Partition coefficients and their uses. Chem. Rev. 71(6), 525-616.
27. Seelig A., Gottschlich R. and Devant R.M. (1994). A method to determine the ability of drugs to diffuse through the blood-brain barrier. Proc. Natl. Acad. Sci. USA 91, 68-72.
28. oct: A tool for lipophilicity determination in drug discovery. J. Med. Chem. 43, 2922-2928.
29. Potts R.O. and Guy R.H. (1995). A predictive algorithm for skin permeability: The effects of molecular size and hydrogen bond activity. Pharm. Res. 12, 1628-1633.
30. Abraham M.H., Martins F. and Mitchell R.C. (1997). Algorithms for skin permeability using hydrogen bond descriptors - The problem of steroids. J. Pharm. Pharmacol 49, 858-865.
31. Roberts M.S., Pugh W.J., Hadgraft J. and Watkinson A.C. (1995). Epidermal permeability: Penetrant structure relationships. 1. An analysis of methods of predicting penetration of monofunctional solutes from aqueous solutions. Int. J. Pharm. 126, 219-233.
32. Pugh W.J., Roberts M.S. and Hadgraft J. (1996). Epidermal permeability: Penetrant structure relationships. 3. The effect of hydrogen-bonding interaction and molecular size on diffusion across the stratum corneum. Int. J. Pharm. 138, 149-165.
33. Roberts M.S., Pugh W.J. and Hadgraft J. (1996). Epidermal permeability: Penetrant structure relationships. 2. The effect of hydrogen-bonding groups in penetrants on their diffusion through the stratum corneum. Int. J. Pharm. 132, 23-32.
34. Du Plessis J., Pugh J., Judefeind A. and Hadgraft J. (2001). The effect of hydrogen bonding on diffusion across model membranes: Consideration of the number of H-bonding groups. Eur. J. Pharm. Sci. 13, 135-141.
35. Chikhale E.G., NG K-Y., Burton P.S. and Borchardt R.T. (1994). Hydrogen bonding potential as a determinant of the in vitro and in situ blood-brain barrier permeability of peptides. Pharm. Res. 11(3), 412-419.
36. Adson A., Raub T.J., Burton P.S., Barsuhn C.L., Hilgers A.R., Audus K.L. and Ho N.F.H. (1994). Quantitative approaches to delineate paracellular diffusion in cultured epithelial cell monolayers. J. Pharm. Sci. 83, 1529-1536.
37. Pagliara A., Reist M., Geinoz S., Carrupt P.A. and Testa B. (1999). Evaluation and prediction of drug permeation. J. Pharm. Pharmacol. 51, 1339-1357.
38. Pauletti G.M., Okumu F.W. and Borchardt R.T. (1997). Effect of size and charge on the passive diffusion of peptides across Caco-2 monolayers via the paracellular pathway. Pharm. Res. 14(2), 164-168.
39. Tregear R.T. (1966). The permeability of skin to albumin, dextrans and polyvinyl pyrrolidone. J. Investig. Dermatol. 46, 24-27.S
40. Liron Z.V.I. and Cohen S. (1984). Percutaneous absorption of alkanoic acids II: Application of regular solution theory. J. Pharm. Sci. 73, 538-542.
41. Roy S.D. and Flynn G.L. (1989). Transdermal delivery of narcotic analgesics: Comparative permeabilities of narcotic analgesics through human cadaver skin. Pharm. Res. 6, 825-832.
42. Potts R.O. and Guy R.H. (1992). Predicting skin permeability. Pharm. Res. 9, 663-669.
43. Shah M.V., Audus K.L. and Borchardt R.T. (1989). The application of bovine brain microvessel endothelial-cell monolayers grown onto polycarbonate membranes in vitro to estimate the potential permeability of solutes through the blood-brain barrier. Pharm. Res. 6(7), 624-627.
44. Hirohashi T., Terasaki T., Shigetoshi M. and Sugiyama Y. (1997). In vivo and in vitro evidence for non-restricted transport of 2,7-bis(2-carboxyethyl)-5(6)-carboxyfluorescein tetraacetoxymethyl ester at the blood-brain barrier. J. Pharmacol. Exp. Ther. 280(2), 813-819.
45. Gaillard P.J. and De Boer A.G. (2000). Relationship between permeability status of the blood-brain barrier and in vitro permeability coefficient of the drug. Eur. J. Pharm. Sci. 12, 95-102.
46. Lewell X.Q. (1992). A model of the adrenergic2 receptor and biding sites for agonist and antagonist. Drug Des. Discovery 9, 29-48.
47. Murray J.S., Gagarin S.G. and Politzer P. (1995). Representation of C60 solubilities in terms of computed molecular surface electrostatic potentials and areas. J. Phys. Chem. 99, 12081-12083.
48. Morelock M.M., Choi L.L., Bell G.L. and Wright J.L. (1994). Estimation and correlation of drug water solubility with pharmacological parameters required for biological activity. J. Pharm. Sci. 83, 948-952.
49. Idson B. (1975). Percutaneous absorption. J. Pharm. Sci. 64, 901-924.
50. Kemken J., Zilger A. and Muller B.W. (1992). Influence of supersaturation on the pharmacodynamic effect of bupranolol after dermal administration using micro-emulsions as vehicle. Pharm. Res. 9, 554-558.
51. Dankwerts M.P. (1991). Advances in topical and transdermal drug delivery. Part 1: Percutaneous absorption and transdermal parches. S. Afr. Pharm. J. Nov., 314-318.
52. Hashiguchi T., Yasutake T., Manako T. and Otagiri M. (1997). In vitro percutaneous absorption of prednisolone derivatives based on solubility parameter. Int. J. Pharm. 158, 11-18.
53. Tojo K., Chiang C.C. and Chien Y.W. (1987). Drug permeation across the skin. Effect of penetrant hydrophilicity. J. Pharm. Sci. 76, 123-126.
54. Hicks D.C. (1973). The buccal absorption of some -adrenoceptor blocking drugs. Br. J. Pharmacol. 47(3), 680-681.
55. Chou C-H., McLachlan A.J. and Rowland M. (1995). Membrane permeability and lipophilicity in the isolated perfused rat liver: 5-ethyl barbituric acid and other compounds. J. Pharmacol. Exp. Ther. 275(2), 933-940.
56. Barr M. (1962). Percutaneous absorption. J. Pharm. Sci. 51, 395-409.
57. Abdou H.M. (1989). Dissolution, Bioavailability and Bioequivalence. Mack, Easton, PA.
58. Wiechers J.W. (1989). The barrier function of the skin in relation to percutaneous absorption of drugs. Pharm. Weekblad. (Sci. Ed.) 11, 185-198.
59. Walker I., Nicholls D., Irwin W.J. and Freeman S. (1994). Drug delivery via active transport at the blood-brain barrier: Affinity of a prodrug of phosphonoformate for the large amino acid transporter. Int. J. Pharm. 104, 157-167.
60. Stenberg P., Luthman K., Ellens H., Lee C.P., Smith P.L., Lago A., Elliott J.D. and Artusson P. (1999). Prediction of the intestinal absorption of endothelin receptor antagonists using three theoretical models of increasing complexity. Pharm. Res. 16(10), 1520-1526.
61. El-Tayar N., Tsai R.S., Testa B., Carrupt P.A., Hansch C. and Leo A. (1991). Percutaneous penetration of drugs: A quantitative structure-permeability relationship study. J. Pharm. Sci. 80, 744-749.
62. Palm K., Stenberg P., Luthman K. and Artusson P. (1997). Polar molecular surface properties predict the intestinal absorption of drugs in humans. Pharm. Res. 14, 568-571.
63. Gaillard P., Carrupt P-A., Testa B. and Boudon A. (1994). Molecular lipophilicity potential, a tool in 3D QSAR: Method and applications. J. Comput. Aided Mol. Des. 8, 83-96.
64. Raevsky O.A., Fetisov V.I., Trepalina E.P., McFarland J.W. and Schaper K.J. (2000). Quantitative estimation of drug absorption in humans for passively transported compounds on the basis of their physico-chemical parameters. Quant. Struct.-Act. Relat. 19(4), 366-374.
65. Sugawara M., Takekuma Y., Yamada H., Kobayashi M., Iseki K. and Miyazaki K. (1998). A general approach for the prediction of the intestinal absorption of drugs: Regression analysis using the physicochemical properties and drug-membrane electrostatic interaction. J. Pharm. Sci. 87(8), 960-966.
66. Winiwarter, S., Bonham, N.M., Ax, F., Hallberg, A., Lennerhans, H and Karlen, A. (1998). Correlation of human jejunal permeability (in vivo) of drugs with experimentally and theoretically derived parameters. A multivariate data analysis approach. J. Med. Chem. 41(25), 4939-4949.
67. Ren S. and Lien E.J. (2000). Caco-2 cell permeability vs human gastrointestinal absorption: QSPR analysis. Prog. Drug Res. 54, 1-23.
68. Roberts M.S., Anderson R.A. and Swarbrick J. (1977). Permeability of human epidermis to phenolic compounds. J. Pharm. Pharmacol. 29, 677-683.
69. Cronin M.T., Dearden J.C., Moss G.P. and Murray-Dickson G. (1999). Investigation of the mechanism of flux across human skin in vitro by quantitative structure-permeability relationships. Eur. J. Pharm. Sci. 7(4), 325-330.
70. Clark D.E. (1999). Rapid calculation of polar molecular surface area and its application to the prediction of transport phenomena. 2. Prediction of blood-brain barrier penetration. J. Pharm. Sci. 88(8), 815-821.
71. Ertl P, Rohde B. and Selzer P. (2000). Fast calculation of molecular polar surface area as a sum of fragment-based contributions and its application to the prediction of drug transport properties. J. Med. Chem. 43, 3714-3717.
72. Feher M., Sourial E. and Schmidt J.M. (2000). A simple model for the prediction of blood-brain partitioning. Int. J. Pharm. 201, 239-247.
73. Norinder U., Österberg T. and Artusson P. (1997). Theoretical calculation and prediction of Caco-2 cell permeability using Molsurf parametrization and PLS statistics. Pharm. Res. 14, 1785-1790.
74. Österberg T. and Norinder U. (2000). Prediction of drug transport processes using simple parameters and PLS statistics: The use of ACD/logP and ACD/ChemSketch descriptors. Eur. J. Pharm. Sci. 12,327-337.
75. Cruciani G., Pastor M. and Guba W. (2000). VolSurf: A new tool for the pharmacokinetic optimisation of lead compounds. Eur. J. Pharm. Sci. 11 Suppl. 2, S29-S39.
76. Kang Y.S. and Pardridge W.M. (1994). Brain delivery of biotin bound to a conjugate of neutral avidin and cationised human albumin. Pharm. Res. 11, 1257-1264.
77. Pardridge W.M. (1999). Non-invasive drug delivery to the human brain using endogenous blood-brain barrier transport systems. Pharm. Sci. Technol. Today 2, 49-59.
78. Derossi D, Chassaing G and Prochiantz A. (1998). Trojan peptides: The penetration system for intracellular delivery. Trends Cell. Biol. 8(2), 84-87.